Edinburgh Research Explorer

Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans

Research output: Contribution to journalArticle

Related Edinburgh Organisations

Open Access permissions

Open

Documents

  • Download as Adobe PDF

    Final published version, 4.44 MB, PDF document

    Licence: Creative Commons: Attribution (CC-BY)

Original languageEnglish
Pages (from-to)367-380.e7
JournalCell Reports
Volume30
Issue number2
DOIs
Publication statusPublished - 14 Jan 2020

Abstract

Recent discoveries have implicated the gut microbiome in the progression and severity of Parkinson’s disease; however, how gut bacteria affect such neurodegenerative disorders remains unclear. Here, we report that the Bacillus subtilis probiotic strain PXN21 inhibits α-synuclein aggregation and clears preformed aggregates in an established Caenorhabditis elegans model of synucleinopathy. This protection is seen in young and aging animals and is partly mediated by DAF-16. Multiple B. subtilis strains trigger the protective effect via both spores and vegetative cells, partly due to a biofilm formation in the gut of the worms and the release of bacterial metabolites. We identify several host metabolic pathways differentially regulated in response to probiotic exposure, including sphingolipid metabolism. We further demonstrate functional roles of the sphingolipid metabolism genes lagr-1, asm-3, and sptl-3 in the anti-aggregation effect. Our findings provide a basis for exploring the disease-modifying potential of B. subtilis as a dietary supplement.

    Research areas

  • probiotics, B. subtilis, C. elegans, α-synuclein, microbiota, Parkinson’s disease, DAF-16/FOXO, dietary restriction, sphingolipid metabolism, biofilm

Download statistics

No data available

ID: 131008132